www.nature.com/scientificreports
OPEN
Corrigendum: Dual modulation of Ras-Mnk and PI3K-AKT-mTOR pathways: A Novel c-FLIP inhibitory mechanism of 3-AWA mediated translational attenuation through dephosphorylation of eIF4E Reyaz ur Rasool, Bilal Rah, Hina Amin, Debasis Nayak, Souneek Chakraborty, Abdul Rawoof, Mubashir Javed Mintoo, Khalid Yousuf, Debaraj Mukherjee, Lekha Dinesh Kumar, Dilip Manikaro Mondhe & Anindya Goswami Scientific Reports 6:18800; doi: 10.1038/srep18800; published online 05 January 2016; updated on 17 February 2016 This Article contains typographical errors. In the Results section under subheading ‘In vivo anticancer activity against Ehrlich ascites Carcinoma (EAC)’ “The experimental results showed that 3-AWA reduced Ehrlich ascites carcinoma by 71.75% at 10 mg/kg intraperitoneal dose in comparison to the tumor growth inhibition of 87.4% in 5-FU (22 mg/kg i.p.) treated group.” should read: “The experimental results showed that 3-AWA reduced Ehrlich ascites carcinoma by 70.5% at 10 mg/kg intraperitoneal dose in comparison to the tumor growth inhibition of 87.4% in 5-FU (22 mg/kg i.p.) treated group.” In the legend of Table 1 “Values are mean ± S.E. (n = 7, 10 for control).” should read: “Values are mean ± S.E. (n = 8).” This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Scientific Reports | 6:21054 | DOI: 10.1038/srep21054
1
OPEN
Corrigendum: Dual modulation of Ras-Mnk and PI3K-AKT-mTOR pathways: A Novel c-FLIP inhibitory mechanism of 3-AWA mediated translational attenuation through dephosphorylation of eIF4E Reyaz ur Rasool, Bilal Rah, Hina Amin, Debasis Nayak, Souneek Chakraborty, Abdul Rawoof, Mubashir Javed Mintoo, Khalid Yousuf, Debaraj Mukherjee, Lekha Dinesh Kumar, Dilip Manikaro Mondhe & Anindya Goswami Scientific Reports 6:18800; doi: 10.1038/srep18800; published online 05 January 2016; updated on 17 February 2016 This Article contains typographical errors. In the Results section under subheading ‘In vivo anticancer activity against Ehrlich ascites Carcinoma (EAC)’ “The experimental results showed that 3-AWA reduced Ehrlich ascites carcinoma by 71.75% at 10 mg/kg intraperitoneal dose in comparison to the tumor growth inhibition of 87.4% in 5-FU (22 mg/kg i.p.) treated group.” should read: “The experimental results showed that 3-AWA reduced Ehrlich ascites carcinoma by 70.5% at 10 mg/kg intraperitoneal dose in comparison to the tumor growth inhibition of 87.4% in 5-FU (22 mg/kg i.p.) treated group.” In the legend of Table 1 “Values are mean ± S.E. (n = 7, 10 for control).” should read: “Values are mean ± S.E. (n = 8).” This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Scientific Reports | 6:21054 | DOI: 10.1038/srep21054
1
